For reducing complement activation due to FH deficiency, drug compounds targeting C3, FB, C5, FP, C3b, C3bB, and C3 convertase are predicted to be efficacious in reducing disease severity (Figure 10). The gene discussed is C5; the disease is hyperinsulinemic hypoglycemia, familial, 4.